The estimated Net Worth of Anne Clem Whitaker is at least $2.56 Million dollars as of 5 November 2020. Ms. Whitaker owns over 29,248 units of Mallinckrodt Plc stock worth over $3,833 and over the last 11 years she sold MNK stock worth over $2,153,024. In addition, she makes $400,000 as Independent Director at Mallinckrodt Plc.
Anne has made over 6 trades of the Mallinckrodt Plc stock since 2015, according to the Form 4 filled with the SEC. Most recently she sold 29,248 units of MNK stock worth $1,987,109 on 5 November 2020.
The largest trade she's ever made was selling 29,248 units of Mallinckrodt Plc stock on 5 November 2020 worth over $1,987,109. On average, Anne trades about 1,254 units every 76 days since 2013. As of 5 November 2020 she still owns at least 11,274 units of Mallinckrodt Plc stock.
You can see the complete history of Ms. Whitaker stock trades at the bottom of the page.
Anne Clem Whitaker has been appointed as Independent Director of the Company. Ms. Whitaker has held the role of chief executive officer Dance Biopharm Holding Inc. since October 2018 and has been a director of Dance Biopharm since August 2018. She has also served as the managing partner of the Anne Whitaker Group, LLC since April 2018 and served as chief executive officer at KNOW Bio, LLC and Novoclem Therapeutics, Inc., a wholly-owned subsidiary of KNOW Bio from February 2017 until April 2018. Previously with Valeant Pharmaceuticals from 2015 to 2017, Ms. Whitaker served as executive vice president and company group chairman with responsibility for the company’s branded pharmaceutical segment including key businesses like Salix, Dendreon, and Orapharma as well as the Canadian and Western Europe regions. Prior to that she served as president and chief executive officer of Synta Pharmaceuticals Corp. from 2014 to 2015; as president of North America pharmaceuticals and consumer health at Sanofi S.A. from 2011-2014; and in roles at GSK, most recently as senior vice president and business unit head of the Cardiovascular, Metabolic and Urology Division. Ms. Whitaker has been a director of Cree Inc. and a member of its Compensation Committee since 2013 and a non-executive director of Vectura Group PLC, a London Stock Exchange listed pharmaceutical and medical device company, since June 2018. Previously she served as a director on the board of Synta Pharmaceuticals Corp. from 2014 to 2015. Ms. Whitaker’s qualifications to serve on our Board include her significant experience in executive positions in the pharmaceutical industry, in both commercial and organizational development roles, as well as her experience as a director of publicly traded and private companies.
As the Independent Director of Mallinckrodt Plc, the total compensation of Anne Whitaker at Mallinckrodt Plc is $400,000. There are 11 executives at Mallinckrodt Plc getting paid more, with Mark Trudeau having the highest compensation of $14,610,800.
Anne Whitaker is 53, she's been the Independent Director of Mallinckrodt Plc since 2018. There are 12 older and 1 younger executives at Mallinckrodt Plc. The oldest executive at Mallinckrodt Plc is J. Martin Carroll, 70, who is the Independent Director.
Anne's mailing address filed with the SEC is 220 EAST FIRST STREET, , BETHLEHEM, PA, 18015.
Over the last 11 years, insiders at Mallinckrodt Plc have traded over $29,853,069 worth of Mallinckrodt Plc stock and bought 2,559,592 units worth $174,429,961 . The most active insiders traders include & Co. Inc. Paulson, James E Deerfield Mgmt L.P...., and Nancy Lurker. On average, Mallinckrodt Plc executives and independent directors trade stock every 29 days with the average trade being worth of $10,061. The most recent stock trade was executed by Jason Daniel Goodson on 16 March 2023, trading 1,133 units of MNK stock currently worth $9,495.
mallinckrodt is a global specialty biopharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. areas of focus include therapeutic drugs for autoimmune and rare disease specialty areas like neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal respiratory critical care therapies; and analgesics and central nervous system drugs. the company's core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities. the company's specialty brands segment includes branded medicines; its specialty generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing; and the global medical imaging segment includes contrast media and nuclear imaging agents. to learn more about mallinckrodt, visit
Mallinckrodt Plc executives and other stock owners filed with the SEC include: